P-154

Growth-promoting effects of vosoritide in children with achondroplasia aged ≥ 10 years at treatment initiation: results from a Phase 3 extension study

Ravi Savarirayan[1], Louise Tofts[2], Melita Irving[3], William R. Wilcox4, Paul R. Harmatz[5], Frank Rutsch6, Ricki Carroll[7], Lynda E. Polgreen[8], Klaus Mohnike[9], Joel Charrow[10], Carlos Prada[10], Daniel Hoernschemeyer[11], Keiichi Ozono[12], Takuo Kubota[12], Yasemin Alanay13, Paul Arundel[14], Natsuo Yasui[15], Klane K. White[16], Shelley Brandstetter[17], Howard M. Saal[18], Hiroshi Mochizuki[19], Asako Tajima[19], Donald Basel[20], Swati Mukherjee[21], Michael Harris[21], Sheetal Ingole21, Andrea Low[22], Julie E. Hoover-Fong[23], Aída Spilack[24]

[1]Murdoch Children's Research Institute, Royal Children's Hospital, and University of Melbourne, Parkville, Australia; [2]Kids Rehab, The Children's Hospital at Westmead, Westmead, Australia; [3]Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK; [4]Emory University, Atlanta, GA, USA; [5]UCSF Benioff Children's Hospital, Oakland, CA, USA; [6]Department of General Pediatrics, Münster University, Münster, Germany; [7]Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE, USA; [8]Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA; [9]Otto-von-Geuricke Universität, Magdeburg, Germany; [10]Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA; [11]University of Missouri-Columbia, Columbia, MO, USA; [12]Osaka University Hospital, Osaka, Japan; [13]Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey; [14]Sheffield Children's NHS Foundation Trust, Sheffield Children's Hospital, Sheffield, UK; [15]Tokushima University Hospital, Tokushima, Japan; [16]Colorado Children's Hospital, Aurora, CO, USA; [17]Seattle Children's Hospital, Seattle, WA, USA; [18]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; [19]Saitama Children's Hospital, Saitama, Japan; [20]Medical College of Wisconsin, Milwaukee, WI, USA; [21]BioMarin (UK) Limited, London, UK; [22]BioMarin Pharmaceutical Inc., Novato, CA, USA; [23]Johns Hopkins University School of Medicine, Baltimore, MD, USA; , [24]BioMarin Farmacêutica do Brasil LTDA, São Paulo, Brasil

Background

Vosoritide: targeted therapy for achondroplasia

- Achondroplasia (ACH) is the most common form of disproportionate short stature (approximately 1:25,000 live births)[1,2]
- ACH is caused by a pathogenic variant in fibroblast growth factor receptor[3]
- (FGFR3) that constitutively activates the downstream inhibitory signaling pathway in chondrocytes, leading to impaired endochondral bone growth and multiple complications[1,2]
- C-type natriuretic peptide (CNP) down-regulates aberrant FGFR3 signaling in chondrocytes by inhibiting the mitogen-activated protein kinase (MAPK)-extracellular-signal-regulated kinases 1 and 2 (ERK1/2) pathway (Figure 1)[3,4]
- Vosoritide, a potent stimulator of endochondral bone growth, is based on a naturally-occurring CNP engineered to resist degradation and increase the half-life.[5] It is approved for use in children with ACH and open epiphyses from birth in the USA, Japan, and Australia, aged ≥4 months in the European Union, and ≥6 months in Brazil

Figure 1. Vosoritide is a CNP pharmacologic analogue that inhibits FGFR3 downstream signaling



Figure modified from Lorget F, et al. *Am J Hum Genet.* 2012;91(6):1108-14.
cGMP, guanosine 3',5'-cyclic monophosphate; CNP, C-type natriuretic peptide; ERK1/2, extracellular signal-regulated kinase 1 and 2; FGFR3, fibroblast growth factor receptor 3; FRS2, fibroblast growth factor receptor substrate 2; GRB2, growth factor receptor-bound protein 2; Ig, immunoglobulin module; MEK1/2, mitogen-activated protein kinase kinase 1 and 2; NPR-B, natriuretic peptide receptor B; PKGII, protein kinase G II; RAF-1, rapidly accelerated fibrosarcoma-1; RAS, rat sarcoma; SOS, son of sevenless.

Increase in growth for children with ACH was demonstrated with vosoritide in clinical trials

- An open-label, 104-week, phase 2 trial (BMN 111-202; NCT02055157) and its extension study (BMN 111-205; NCT02724228) in children with ACH showed that vosoritide treatment resulted in sustained increases in annualized growth velocity (AGV)[6]
- In children with ACH of 0 to 5 years of age, improvement in height Z-score was seen with vosoritide compared to placebo after 52 weeks (BMN 111-206; NCT03583697)[7]
- A phase 3, randomized, placebo-controlled trial (BMN 111-301; NCT03197766) in children with ACH showed a statistically significant improvement in AGV with vosoritide after 52 weeks compared to placebo8; AGV improvement was sustained after 2 years of vosoritide treatment in the extension study (BMN 111-302; NCT03424018)[9]
- Here, we report efficacy and safety data from the subset of children in a phase 3 trial (BMN 111-301) and its extension (BMN 111-302) who started vosoritide treatment at age 10 years or older

Methods

- After completion of a 52-week, phase 3, placebo-controlled trial (BMN 111-301), participants transitioned to an open-label extension study (BMN 111-302), where they continued to receive vosoritide (Figure 2)
  - Key objectives: evaluate the long-term safety, tolerability, and efficacy (linear growth, proportionality) of daily subcutaneous injections of vosoritide in children with ACH

Figure 2. BMN 111-301/302 study design



[a]The majority of individuals had transitioned to weight-band dosing.
VOS, vosoritide.

Key eligibility criteria for BMN 111-301

- Age 5 to <18 years old at screening
- ACH, documented by clinical grounds and confirmed by genetic testing
- Stratified capped enrollment ≤20% Tanner stage >1
- Primary efficacy endpoint: AGV
- Secondary efficacy endpoints: height Z-score; upper to lower body segment ratio

Subgroup analysis

- Of the 119 participants who entered the extension study, 49 participants received their first dose of vosoritide when they were ≥10 years of age on day 1 of BMN 111-301 or day 1 of BMN 111-302 (if they were previously receiving placebo in BMN 111-301)
- Per protocol, participants were required to discontinue vosoritide when they reached near-final adult height (defined as evidence of growth plate closure and <1.5 cm/y AGV)
- Efficacy was assessed using 12-month-interval AGV by age intervals referenced to ACH untreated AGV10 and average-stature AGV11
- Safety was assessed with rate of adverse events (AEs)
- The data cutoff date for this analysis was February 25, 2023

Results

Participants

Table 1. Demographics of BMN 111-301/302 study participants who received their first vosoritide dose at ≥10 years of age

	301/302 (N = 49)
Age at day 1 of treatment (y)	
Mean (SD)	11.81 (1.32)
Min, max	10.0, 15.9
Age subgroups (%)	
≥10 to <11 years	13 (26.5)
≥11 to <15 years	35 (71.4)
≥15 to <18 years	1 (2.0)
Sex (%)	
Male	24 (49.0)
Female	25 (51.0)

max, maximum; min, minimum; SD, standard deviation.

- There were 25 females and 24 males who received their first dose of vosoritide by ≥10 years of age (Table 1)
- At treatment start, there were 19 females and 8 males at a Tanner stage >1

Figure 3. BMN 111-302 study disposition



[a]Nearing final adult height, limb lengthening, injection burden, other

- The mean (standard deviation [SD]; range) treatment exposure time was 3.57 (0.80; 2.00–4.83) years for females and 3.87 (0.52; 2.97–5.03) years for males, with 31 (63%) still on treatment at the time of the data cut (Figure 3)

No evidence of acceleration of bone age with vosoritide

Figure 5. Mean sex-specific bone age/chronological age ratio for children treated with vosoritide



Data are the interquartile range (boxes), median value (horizontal line), mean value (circle symbol), and minimum and maximum values (whiskers).

- Vosoritide treatment had no adverse effects on bone age in male or female children (Figure 5)

AGV with vosoritide is consistently higher compared with age-matched untreated children with ACH

Figure 4. Mean age- and sex-specific AGVs for children treated with vosoritide compared with untreated ACH and average-stature children



The Tanner stages for participants in each age range are reported in **Table 2**.
ACH untreated reference derived from the CLARITY study,[10] and average stature reference is non-African American data from Kelly et al.[11]
ACH, achondroplasia; AGV, annualized growth velocity; SD, standard deviation; VOS, vosoritide.

- Based on summary statistics, mean age- and sex-specific AGVs were consistently higher in children treated with vosoritide than in untreated controls from the CLARITY ACH natural history data set10 across all age groups (Figure 4)
- The mean (SD) difference in AGV across integer ages 10 to 17 years between children with ACH who were treated and untreated was 1.47 (0.63) cm/y in females and 1.71 (0.63) cm/y in males

Table 2. Tanner stages for each sex-specific AGV year assessed in Figure 4

	Tanner stages for females						Tanner stages for males					
	I	II	III	IV	V	Total	I	II	III	IV	V	Total
10 years	1		2			3	2					2
11 years	1	5	1	2		9	4	5				9
12 years		4	8	7	1	20	3	3	8			14
13 years		1	4	13	3	21	2	3	6	5		16
14 years			2	5	9	16		4	2	6	3	15
15 years					6	6			1	4	6	11
16 years				1	1	2				2	5	7
17 years				1		1					4	4

The Tanner stages at each integer year are reported for female and male participants with AGV assessments shown in **Figure 4**
AGV, annualized growth velocity.

- The growth benefits depicted in Figure 4 occurred regardless of the individual's Tanner stage (Table 2)

BMN 111-301/302 safety summary

Table 3. BMN 111-301/302 incidence of AEs for individuals who received their first dose of vosoritide at ≥10 years of age

	Overall N = 49; 176.77 person-years	
	Incidence n (%)	Event rate (AEs/person-year)
AE, n (%)	49 (100)	656 (3.71)
Treatment-related AEs	13 (26.5)	37 (0.21)
AEs leading to study drug discontinuation	1 (2.0)	1 (0.01)
SAEs	9 (18.4)	11 (0.06)
Treatment-related SAEs	1 (2.0)	2 (0.01)
SAEs leading to study drug discontinuation	1 (2.0)	1 (0.01)
AEs CTCAE grade ≥3	7 (14.3)	10 (0.06)
Event of interest		
Injection site reactions CTCAE grade ≥2	2 (4.1)	5 (0.03)
Injection site reactions lasting >24 hours (excluding bruising)	1 (2.0)	11 (0.06)
Hypotension	7 (14.3)	9 (0.05)
Heart rate change	1 (2.0)	1 (0.01)
Hypersensitivity (SMQ narrow terms)	7 (14.3)	14 (0.08)
Avascular necrosis or osteonecrosis	0	0
Slipped capital femoral epiphysis	0	0
Fractures	4 (8.2)	5 (0.03)

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event; SMQ, standard MedDRA query.

- Most AEs were mild and generally comparable to the experience of younger children (Table 3)
- One participant discontinued vosoritide due to a serious AE of kyphoscoliosis that was assessed as related to vosoritide by the investigator
- No other participant discontinued vosoritide due to an AE

Conclusions

- Vosoritide was well tolerated and improved AGV in children even when starting treatment at adolescence
- Additionally, the AGV improvement persisted during the later stages of puberty
- Treatment with vosoritide was not associated with serious or treatment-limiting adverse drug reactions, and no pathological acceleration was observed in bone age

Acknowledgements

We thank Renee Shediac, Yumiko Kotani, and Antonio Leiva- Gea for their contributions developing the abstract. Funding for this study was provided by BioMarin Pharmaceutical Inc. Medical writing support was provided by Tony Sallese, PhD, of AlphaBioCom, a Red Nucleus company, and funded by BioMarin Pharmaceutical Inc.

Disclosures

All authors are investigators in this clinical trial except for SM, MH, SI, and AL, who are employees and potential stockholders of BioMarin Pharmaceutical Inc. RS, LT, FR, and KM have received consulting fees and grants from BioMarin Pharmaceutical Inc. MI and WRW have received consulting fees from BioMarin Pharmaceutical Inc. PRH has received consulting fees, honoraria and grants from BioMarin Pharmaceutical Inc. RC, LEP, and PA have received honoraria from BioMarin Pharmaceutical Inc. JC and DB have received grants from BioMarin Pharmaceutical Inc. KKW has received consulting fees from
BioMarin Pharmaceutical Inc. and Sanofi/Genzyme and grants from Ascendis, BioMarin Pharmaceutical Inc., and Ultragenyx. JEHF has received consulting fees from Alexion, Ascendis,
BioMarin Pharmaceutical Inc., Innoskel, QED, and Therachon AG and grants from Alexion and BioMarin Pharmaceutical Inc. CP, DH, KO, TK, YA, NY, SB, HMS, HM, and AT declare no
competing interests.

References

Horton WA, et al. Lancet. 2007;370(9582):162-72. 2. Hoover-Fong J, et al. Bone. 2021;146:115872. 3. Yasoda A, et al. Nat Med. 2004;10(1):80-6. 4. Krejci P, et al. J Cell Sci. 2005;118(pt 21):5089-100. 5. Lorget F, et al. Am J Hum Genet. 2012;91(6):1108-14.6. Savarirayan R, et al. N Engl J Med. 2019;381(1):25-35. 7. Savarirayan R, et al. Lancet Child Adolesc Health. 2024;8(1):40-50. 8. Savarirayan R, et al. Lancet. 2020;396(10252):684-92. 9. Savarirayan R, et al. Genet Med. 2021;23(12):2443-7. 10. Hoover-Fong JE, et al. Orphanet J Rare Dis. 2021;16(1):522. 11. Kelly A, et al. J Clin Endocrinol Metab. 2014;99(6):2104-12.